← Back to all trials
Active Not Recruiting
NCT05000021
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
Conditions: Type 1 Diabetes
Sex: All
Ages: 18 Years – 64 Years
Healthy volunteers: No
Phase: NA
Enrollment: 96
Sponsor: Albert Einstein College of Medicine
Location: Yeshiva University New York New York
Summary
This project proposes to use telemedicine-delivered cognitive-behavioral therapy (CBT) enhanced with continuous glucose monitor (CGM) review to target diabetes distress in adults with type 1 diabetes. The efficacy of CBT for diabetes distress (CBT-DD) will be tested in comparison to commercial FDA-approved CGM only in a randomized controlled clinical trial. The investigators' central hypothesis is that the addition of a CBT intervention that targets diabetes distress and self-management directly will yield clinically significant improvements in both diabetes distress and glycemic control relative to CGM alone. The investigators propose to recruit 93 adults (age 18-64) with type 1 diabetes from a national population for an entirely virtual 6-month study over four years, with targeted recruitment of racial/ethnic minorities. In addition to standard measurement of HbA1c for glycemic control and validated patient-reported outcome (PRO) surveys, the investigators plan to innovatively integrate momentary psychological and behavioral data via smartphone-based ecological momentary assessment with CGM data to assess day-to-day changes in diabetes distress, affect, self-management, and glycemia over the course of the trial.
Eligibility Criteria
Inclusion Criteria:
* Type 1 Diabetes (T1D) duration ≥6 months
* English or Spanish speaking
* At least moderate Diabetes Distress (DD) (score of ≥2 on T1D-Diabetes Distress Scale)
* Stable insulin treatment regimen (insulin prescription, use of pump, etc.) for at least 3 months prior to study enrollment
Exclusion Criteria:
* Comorbid psychiatric condition, including depression, anxiety, or suicidality, which may be independently associated with the main outcomes of DD or glycemic control. Comorbid psychiatric conditions listed above are being excluded because CBT-DD currently centers on mitigating specifically diabetes distress to improve glycemic outcomes
* In treatment for a psychological condition within the last 6 months or on a non-stable dose of psychiatric medication over the last 2 months
* Developmental or sensory disability interfering with participation
* Current pregnancy, as self-management and glycemic goals differ
* Participation in another behavioral intervention study
* Use of non-insulin medications or recent medical procedures that would impact glycemic control or use of CGM over the study
* Minors
* Subjects who do have the capacity to consent
Source: ClinicalTrials.gov (NCT05000021). StuddyBuddy aggregates publicly available trial information.